10x Genomics $TXG Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al reduced its position in shares of 10x Genomics (NASDAQ:TXG) by 76.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,403 shares of the company’s stock after selling 47,600 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in 10x Genomics were worth $1,301,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TXG. Sei Investments Co. boosted its holdings in 10x Genomics by 113.5% in the 1st quarter. Sei Investments Co. now owns 44,679 shares of the company’s stock valued at $949,000 after purchasing an additional 23,748 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of 10x Genomics in the 2nd quarter valued at approximately $2,069,000. HB Wealth Management LLC acquired a new stake in shares of 10x Genomics during the 2nd quarter worth approximately $285,000. Proficio Capital Partners LLC acquired a new stake in shares of 10x Genomics during the 2nd quarter worth approximately $781,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of 10x Genomics during the 1st quarter worth approximately $5,945,000. 84.68% of the stock is currently owned by institutional investors and hedge funds.

10x Genomics Price Performance

Shares of TXG stock opened at $67.52 on Thursday. The firm has a market cap of $8.80 billion, a PE ratio of -114.44 and a beta of 2.03. The company has a 50-day moving average of $74.19 and a two-hundred day moving average of $41.22. 10x Genomics has a 1-year low of $12.80 and a 1-year high of $102.81.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.10. The business had revenue of $151.04 million during the quarter, compared to analysts’ expectations of $146.67 million. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.33%. The business’s revenue for the quarter was down 12.7% on a year-over-year basis. During the same period last year, the business earned $0.28 earnings per share. Sell-side analysts anticipate that 10x Genomics will post -0.77 EPS for the current fiscal year.

Insider Transactions at 10x Genomics

In related news, CEO Serge Saxonov sold 25,000 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $81.22, for a total transaction of $2,030,500.00. Following the completion of the transaction, the chief executive officer owned 1,050,249 shares of the company’s stock, valued at approximately $85,301,223.78. This trade represents a 2.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director John R. Stuelpnagel sold 20,000 shares of 10x Genomics stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $61.75, for a total transaction of $1,235,000.00. Following the completion of the sale, the director owned 328,436 shares of the company’s stock, valued at $20,280,923. This trade represents a 5.74% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 179,333 shares of company stock worth $11,810,070. 8.84% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

TXG has been the topic of several analyst reports. Royal Bank Of Canada began coverage on shares of 10x Genomics in a research report on Tuesday, September 1st. They set a “sector perform” rating and a $70.00 price target on the stock. Stifel Nicolaus set a $70.00 price objective on 10x Genomics in a research report on Tuesday, October 13th. Morgan Stanley raised their target price on 10x Genomics from $40.00 to $70.00 and gave the stock an “equal weight” rating in a research note on Monday, October 12th. UBS Group started coverage on 10x Genomics in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $68.00 target price on the stock. Finally, Barclays lifted their target price on 10x Genomics from $52.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Five investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, 10x Genomics currently has an average rating of “Hold” and a consensus target price of $68.00.

10x Genomics Company Profile

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.